

# COMPARING EXPANDED GOVERNMENT-MANDATED DRUG PRICING POLICIES

Emerging government-mandated drug pricing policies in Medicare have an impact on medical innovation and jobs. From the recently enacted Inflation Reduction Act (IRA) to the White House's FY2024 Budget Proposal to the Senate's SMART Prices Act – the consequences are expected to worsen under every scheme.



	IRA	WH BUDGET PROPOSAL & SMART PRICES ACT
<p><b>Medicines Eligible for Government-Mandated Price</b></p>	<p><b>10</b> Part D drugs in <b>2026</b></p> <p><b>15</b> Part D drugs in <b>2027</b></p> <p><b>15</b> Part D and Part B drugs in <b>2028</b></p> <p><b>20</b> Part D and Part B drugs in <b>2029</b> and beyond</p>	<p><b>20</b> Part D drugs in <b>2026</b></p> <p><b>40</b> Part D and Part B drugs in <b>2027</b> and beyond</p>
<p><b>Time Limit Between FDA Approval &amp; Mandated Price</b></p>	<p>Small-molecule drugs <b>9 YEARS</b></p> <p>Biologics <b>13 YEARS</b></p>	<p>All drugs <b>5 YEARS</b></p>
<p><b>U.S. Jobs Lost</b></p>	<p><b>~400,000 – 800,000</b> total jobs</p> <p><b>66,800 – 135,900</b> direct</p> <p><b>342,000 – 676,000</b> indirect</p>	<p><b>~730,000 – 1.1 million</b> total jobs</p> <p><b>146,000 – 223,000</b> direct</p> <p><b>584,000 – 877,000</b> indirect</p>
<p><b>Future Therapies Lost</b></p>	<p><b>139</b> fewer therapies over <b>10 years</b></p>	<p><b>237</b> fewer therapies over <b>10 years</b></p>

Gassull, Daniel et. al. *IRA's Impact on the US Biopharma Ecosystem*. [Vital Transformation](#), June 1, 2023.  
 Bowen, Harry et. al. *The Impact of IRA Policy Expansion Proposals on the US Biopharma Ecosystem*. [Vital Transformation](#), June 15, 2023.